The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review

Lee, 2013, Risk and prognostic factors for acute GVHD based on NIH consensus criteria, Bone Marrow Transplant, 48, 587, 10.1038/bmt.2012.187 Ferrara, 2009, Graft-versus-host disease, Lancet, 373, 1550, 10.1016/S0140-6736(09)60237-3 Iqbal, 2000, Diagnosis of gastrointestinal graft-versus-host disease, Am J Gastroenterol, 95, 3034, 10.1111/j.1572-0241.2000.03250.x Roy, 1991, Simultaneous upper and lower endoscopic biopsy in the diagnosis of intestinal graft-versus-host disease, Transplantation, 51, 642, 10.1097/00007890-199103000-00019 McDonald, 2016, How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver, Blood, 127, 1544, 10.1182/blood-2015-10-612747 Martin, 2012, First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 18, 1150, 10.1016/j.bbmt.2012.04.005 Dignan, 2012, Diagnosis and management of acute graft-versus-host disease, Br J Haematol, 158, 30, 10.1111/j.1365-2141.2012.09129.x Bombí, 1995, Assessment of histopathologic changes in the colonic biopsy in acute graft-versus-host disease, Am J Clin Pathol, 103, 690, 10.1093/ajcp/103.6.690 Ponec, 1999, Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation, Gastrointest Endosc, 49, 612, 10.1016/S0016-5107(99)70390-1 Liakopoulou, 2005, Rotavirus as a significant cause of prolonged diarrhoeal illness and morbidity following allogeneic bone marrow transplantation, Bone Marrow Transplant, 36, 691, 10.1038/sj.bmt.1705127 Selbst, 2009, Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil, Mod Pathol, 22, 737, 10.1038/modpathol.2009.44 Alonso, 2012, Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients, Clin Infect Dis, 54, 1053, 10.1093/cid/cir1035 Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825 Rowlings, 1997, IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade, Br J Haematol, 97, 855, 10.1046/j.1365-2141.1997.1112925.x MacMillan, 2015, A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality, Biol Blood Marrow Transplant, 21, 761, 10.1016/j.bbmt.2015.01.001 Harris, 2016, International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium, Biol Blood Marrow Transplant, 22, 4, 10.1016/j.bbmt.2015.09.001 Ruutu, 2014, Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice, Bone Marrow Transplant, 49, 168, 10.1038/bmt.2013.107 Mielcarek, 2015, Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial, Haematologica, 100, 842, 10.3324/haematol.2014.118471 MacMillan, 2002, Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems, Biol Blood Marrow Transplant, 8, 387, 10.1053/bbmt.2002.v8.pm12171485 Levine, 2010, Graft-versus-host disease treatment: predictors of survival, Biol Blood Marrow Transplant, 16, 1693, 10.1016/j.bbmt.2010.05.019 Gooley, 2010, Reduced mortality after allogeneic hematopoietic-cell transplantation, N Engl J Med, 363, 2091, 10.1056/NEJMoa1004383 Jenq, 2010, Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer, Nat Rev Cancer, 10, 213, 10.1038/nrc2804 Lochmanová, 2012, Potential biomarkers for early detection of acute graft-versus-host disease, Proteomics Clin Appl, 6, 351, 10.1002/prca.201100104 Lau, 2007, Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease, Transplantation, 83, 839, 10.1097/01.tp.0000258731.38149.61 Magenau, 2010, Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease, Biol Blood Marrow Transplant, 16, 907, 10.1016/j.bbmt.2010.02.026 Teshima, 2011, Regulatory T cells and IL-17–producing cells in graft-versus-host disease, Immunotherapy, 3, 833, 10.2217/imt.11.51 Ranganathan, 2012, Regulation of acute graft-versus-host disease by microRNA-155, Blood, 119, 4786, 10.1182/blood-2011-10-387522 Xie, 2014, Serum microRNA155 is increased in patients with acute graft-versus-host disease, Clin Transplant, 28, 314, 10.1111/ctr.12314 Wang, 2015, Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease, Ann Hematol, 94, 1505, 10.1007/s00277-015-2414-z Xiao, 2013, Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease, Blood, 122, 3365, 10.1182/blood-2013-06-510586 Vander Lugt, 2013, ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death, N Engl J Med, 369, 529, 10.1056/NEJMoa1213299 Ponce, 2015, High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation, Blood, 125, 199, 10.1182/blood-2014-06-584789 Lv, 2013, Ceruloplasmin is a potential biomarker for aGVHD following allogeneic hematopoietic stem cell transplantation, PLoS One, 8, e58735, 10.1371/journal.pone.0058735 Choi, 2008, Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival, Blood, 112, 1539, 10.1182/blood-2008-02-138867 Kitko, 2008, Plasma elevations of tumor necrosis factor receptor 1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients, Biol Blood Marrow Transplant, 14, 759, 10.1016/j.bbmt.2008.04.002 Willems, 2010, Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning, Bone Marrow Transplant, 45, 1442, 10.1038/bmt.2009.360 August, 2011, Biomarkers of immune activation to screen for severe, acute GVHD, Bone Marrow Transplant, 46, 601, 10.1038/bmt.2010.165 Dean, 2008, Association of serum interleukin-7 levels with the development of acute graft-versus-host disease, J Clin Oncol, 26, 5735, 10.1200/JCO.2008.17.1314 Thiant, 2011, Plasma levels of IL-7 and IL-15 after reduced-intensity conditioned allo-SCT and relationship to acute GVHD, Bone Marrow Transplant, 46, 1374, 10.1038/bmt.2010.300 Thiant, 2010, Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse, Bone Marrow Transplant, 45, 1546, 10.1038/bmt.2010.13 Cho, 2010, High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 16, 629, 10.1016/j.bbmt.2009.11.023 Zhu, 2015, Increased expression of T cell immune response cDNA 7 in patients with acute graft-versus-host disease, Ann Hematol, 94, 1025, 10.1007/s00277-015-2300-8 Harris, 2012, Plasma biomarkers of lower gastrointestinal and liver acute GVHD, Blood, 119, 2960, 10.1182/blood-2011-10-387357 Ferrara, 2011, Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease, Blood, 118, 6702, 10.1182/blood-2011-08-375006 Reinhardt, 2014, Monocyte-induced development of Th17 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease, J Immunol, 193, 3355, 10.4049/jimmunol.1400983 Rodriguez-Otero, 2012, Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease, Blood, 119, 5909, 10.1182/blood-2011-12-397968 Chiusolo, 2012, Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation, Blood, 120, 4443, 10.1182/blood-2012-08-447326 Oikawa, 2006, Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease, J Immunol, 177, 4281, 10.4049/jimmunol.177.7.4281 Veenstra, 2012, Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells, Blood, 120, 682, 10.1182/blood-2011-10-387977 Hansen, 2013, A novel soluble form of Tim-3 associated with severe graft-versus-host disease, Biol Blood Marrow Transplant, 19, 1323, 10.1016/j.bbmt.2013.06.011 Luft, 2007, Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease, Blood, 110, 4535, 10.1182/blood-2006-10-049817 Luft, 2011, Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system, Blood, 118, 1685, 10.1182/blood-2011-02-334821 Okamoto, 2001, Increased hepatocyte growth factor in serum in acute graft-versus-host disease, Bone Marrow Transplant, 28, 197, 10.1038/sj.bmt.1703095 Paczesny, 2009, A biomarker panel for acute graft-versus-host disease, Blood, 113, 273, 10.1182/blood-2008-07-167098 Paczesny, 2010, Elafin is a biomarker of graft-versus-host disease of the skin, Sci Transl Med, 2, 13ra2, 10.1126/scitranslmed.3000406 Chacon, 2013, Elafin: a possible new biomarker and immunohistochemical stain for pre-engraftment syndrome, J Am Acad Dermatol, 69, e102, 10.1016/j.jaad.2012.11.024 Bartel, 2009, MicroRNAs: target recognition and regulatory functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002 Ng, 2009, Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening, Gut, 58, 1375, 10.1136/gut.2008.167817 Li, 2010, Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma, Cancer Res, 70, 9798, 10.1158/0008-5472.CAN-10-1001 Zampetaki, 2010, Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes, Circ Res, 107, 810, 10.1161/CIRCRESAHA.110.226357 Mas, 2013, MicroRNAs as biomarkers in solid organ transplantation, Am J Transplant, 13, 11, 10.1111/j.1600-6143.2012.04313.x Tili, 2009, miR-155: on the crosstalk between inflammation and cancer, Int Rev Immunol, 28, 264, 10.1080/08830180903093796 Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci USA, 105, 10513, 10.1073/pnas.0804549105 Chang, 2008, Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells, J Virol, 82, 8215, 10.1128/JVI.02575-07 Dinarello, 2011, Interleukin-1 in the pathogenesis and treatment of inflammatory diseases, Blood, 117, 3720, 10.1182/blood-2010-07-273417 Ito, 2015, ST2: the biomarker at the heart of GVHD severity, Blood, 125, 10, 10.1182/blood-2014-11-611780 Reichenbach, 2015, The IL-33/ST2 axis augments effector T-cell responses during acute GVHD, Blood, 125, 3183, 10.1182/blood-2014-10-606830 Schmitz, 2005, IL-33, an interleukin-1–like cytokine that signals via the IL-1 receptor–related protein ST2 and induces T helper type 2–associated cytokines, Immunity, 23, 479, 10.1016/j.immuni.2005.09.015 Henden, 2015, Cytokines in graft-versus-host disease, J Immunol, 194, 4604, 10.4049/jimmunol.1500117 Remberger, 1995, TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD, Bone Marrow Transplant, 15, 99 McDonald, 2015, Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment, Blood, 126, 113, 10.1182/blood-2015-03-636753 Levine, 2012, Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study, Blood, 119, 3854, 10.1182/blood-2012-01-403063 Te Boome, 2015, Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells, Leukemia, 29, 1839, 10.1038/leu.2015.89 Levine, 2015, A prognostic score for acute graft-versus-host disease based on biomarkers: a multicenter study, Lancet Haematol, 2, e21, 10.1016/S2352-3026(14)00035-0 Chung, 2008, Importance of interleukin-7 in the development of experimental graft-versus-host disease, Biol Blood Marrow Transplant, 14, 16, 10.1016/j.bbmt.2007.07.015 Chung, 2007, Prevention of graft-versus-host disease by anti–IL-7Rα antibody, Blood, 110, 2803, 10.1182/blood-2006-11-055673 Savani, 2007, Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell–depleted allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 13, 1216, 10.1016/j.bbmt.2007.07.005 Sarantopoulos, 2009, Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease, Blood, 113, 3865, 10.1182/blood-2008-09-177840 Ratanatharathorn, 2009, Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation, Br J Haematol, 145, 816, 10.1111/j.1365-2141.2009.07674.x Ye, 2004, BAFF binding to T cell–expressed BAFF-R costimulates T cell proliferation and alloresponses, Eur J Immunol, 34, 2750, 10.1002/eji.200425198 Takashima, 2011, The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells, J Exp Med, 208, 285, 10.1084/jem.20101559 Foell, 2004, Proinflammatory S100 proteins in arthritis and autoimmune disease, Arthritis Rheum, 50, 3762, 10.1002/art.20631 Foell, 2008, Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease, J Pathol, 216, 183, 10.1002/path.2394 Kuchroo, 2003, The TIM gene family: emerging roles in immunity and disease, Nat Rev Immunol, 3, 454, 10.1038/nri1111 Geng, 2006, Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell–mediated immune response, J Immunol, 176, 1411, 10.4049/jimmunol.176.3.1411 Monney, 2002, Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease, Nature, 415, 536, 10.1038/415536a Sehrawat, 2010, Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response, PLoS Pathog, 6, e1000882, 10.1371/journal.ppat.1000882 Hastings, 2009, TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines, Eur J Immunol, 39, 2492, 10.1002/eji.200939274 Chu, 2002, Keratin expression in human tissues and neoplasms, Histopathology, 40, 403, 10.1046/j.1365-2559.2002.01387.x Bivén, 2003, A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera, Apoptosis, 8, 263, 10.1023/A:1023672805949 Shulman, 2006, Histopathologic diagnosis of chronic graft-versus-host disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, II: Pathology Working Group Report, Biol Blood Marrow Transplant, 12, 31, 10.1016/j.bbmt.2005.10.023 Matsumoto, 1996, Emerging multipotent aspects of hepatocyte growth factor, J Biochem, 119, 591, 10.1093/oxfordjournals.jbchem.a021283 Nakamura, 1989, Molecular cloning and expression of human hepatocyte growth factor, Nature, 342, 440, 10.1038/342440a0 Shiota, 1995, Serum hepatocyte growth factor levels in liver diseases: clinical implications, Hepatology, 21, 106, 10.1002/hep.1840210119 Hino, 1996, Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells, Br J Cancer, 73, 119, 10.1038/bjc.1996.22 Taniguchi, 1995, Serum concentrations of hepatocyte growth factor in breast cancer patients, Clin Cancer Res, 1, 1031 Nonomura, 1994, Up-regulation of elafin/SKALP gene expression in psoriatic epidermis, J Invest Dermatol, 103, 88, 10.1111/1523-1747.ep12391802 Pfundt, 2000, TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway, Arch Dermatol Res, 292, 180, 10.1007/s004030050475